Solid Biosciences (SLDB) CFO sells shares to cover RSU taxes

Rhea-AI Filing Summary

Solid Biosciences Inc. Chief Financial Officer and Treasurer Kevin Tan reported RSU vesting and related share activity. On February 13, 2026, 10,625 restricted stock units converted into 10,625 shares of common stock at no cost, leaving 21,250 RSUs outstanding and 104,826 common shares held directly.

On February 18, 2026, Tan sold 5,404 common shares at a weighted average price of $5.8233 per share to cover withholding taxes after the RSU vesting, under a durable automatic sales instruction adopted on August 15, 2024. The sale was not a discretionary trade, and he now directly holds 99,422 common shares.

Insider Trade Summary

Net Seller: 5,404 shares ($31,469)

Net Sell 3 txns

Insider Tan Kevin

Role CFO & Treasurer

Sold 5,404 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,404	$5.8233	$31K
Exercise	Restricted Stock Units	10,625	$0.00	--
Exercise	Common Stock	10,625	$0.00	--

Holdings After Transaction: Common Stock — 99,422 shares (Direct); Restricted Stock Units — 21,250 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The restricted stock units were granted on February 13, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Kevin

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		10,625	A	(1)	104,826	D
Common Stock	02/18/2026		S		5,404(2)	D	$5.8233(3)	99,422	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/13/2026		M			10,625	(4)	(4)	Common Stock	10,625	$0.00	21,250	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

4. The restricted stock units were granted on February 13, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Kevin Tan	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Solid Biosciences (SLDB) CFO Kevin Tan report?

Kevin Tan reported RSU vesting and related share movements. 10,625 restricted stock units converted into 10,625 common shares, and 5,404 common shares were sold to cover taxes, with all positions held directly in his name.

How many Solid Biosciences shares did the CFO sell and at what price?

Kevin Tan sold 5,404 shares of Solid Biosciences common stock. The weighted average sale price was $5.8233 per share, with individual trades executed between $5.23 and $6.14, according to the detailed price range disclosure.

Were Kevin Tan’s Solid Biosciences share sales discretionary trades?

The sale was not discretionary. It was executed under a durable automatic sales instruction adopted on August 15, 2024, solely to cover withholding taxes due upon RSU vesting, reflecting a sell-to-cover election rather than an open-market investment decision.

What RSU conversion did Solid Biosciences CFO Kevin Tan report?

He reported the conversion of 10,625 restricted stock units into 10,625 shares of common stock on February 13, 2026. These RSUs represent a contingent right to receive one share each of Solid Biosciences common stock when they vest.

What are the vesting terms of Kevin Tan’s Solid Biosciences RSUs?

The RSUs were granted on February 13, 2025 and vest over four years. Twenty-five percent of the original RSU grant vests on each anniversary of the grant date, until the fourth anniversary completes the vesting schedule, subject to continued service conditions.

How many Solid Biosciences shares and RSUs does the CFO hold after these transactions?

After the reported transactions, Kevin Tan directly holds 99,422 shares of Solid Biosciences common stock. He also holds 21,250 restricted stock units, each representing a contingent right to receive one additional share of common stock upon vesting.